Sino Biopharma spends $951m to acquire China-based LaNova Medicines

finance.yahoo.com/news/sino-biopharma-spends-951m-acquire-154429325.html

Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year.
Sino already owns a 4.91% stake courtesy of an…

This story appeared on finance.yahoo.com, 2025-07-15 15:44:29.
The Entire Business World on a Single Page. Free to Use →